This page shows the latest Alzheimer's drug news and features for those working in and with pharma, biotech and healthcare.
They discovered that only human neurons displayed Alzheimer’s features, including tau tangles and neuronal cell loss. ... These findings suggest that humans have specific factors that play in Alzheimer’s that standard mouse models cannot replicate,
s disease (AD) drug, A11, could reduce inflammation and improve memory. ... After comparing the gene expression of immune cells in post-mortem brain samples from AD patients and AD mouse models, researchers found that Alzheimer’s effected major changes
The deal comes just a few weeks after Biogen and Eisai’s jointly developed Alzheimer’s disease drug was granted traditional approval in the US for use in patients with mild ... The FDA’s decision made Leqembi (lecanemab-irmb) the first approved anti
Biogen and Eisai’s Alzheimer’s disease drug has shown promise as a subcutaneous (SC) formulation, according to new data presented by Eisai at this year’s Alzheimer’s Association International ... tasks. Eli Lilly also presented results from a late
Eli Lilly’s experimental Alzheimer’s drug has been shown to significantly slow cognitive and functional decline in patients with early symptomatic disease, according to phase 3 results presented at this ... The drug, donanemab, is an intravenous
The drug, ACU193, works by targeting and binding to amyloid beta oligomers, a toxic and soluble version of the amyloid protein that forms brain plaques associated with Alzheimer’s disease. ... The US Food and Drug Administration has already granted the
More from news
Approximately 7 fully matching, plus 169 partially matching documents found.
We are expecting to see the outcomes of an FDA priority review of the potential Alzheimer’s drug, aducanumab, this year. ... Over the past two decades, Alzheimer’s drug discovery has largely focused on targeting the hallmark amyloid protein.
Tau is emerging as a target for drug development in Alzheimer’s, as well as other disorders like frontotemporal dementia. ... Organisations including the Alzheimer’s Drug Discovery Foundation (ADDF) think combinations of molecules with these
Biogen and Eisai also pulled the plug on their Alzheimer’s drug aducanumab, after advice from an independent data monitoring committee forced them to abandon the phase 3 Abeta-targeting candidate. ... It was just another in a string of late-stage
This evidence has spurred research and led. organisations including the Alzheimer’s Drug Discovery Foundation and AC Immune to conclude that combination therapies may be needed to tackle such a complex ... Read more: Brain power: fresh approaches to
Two further candidates, AL003 for Alzheimer’s disease and AL004 for multiple degenerative disorders, are also set to enter clinical trials this year. ... Diseases include Alzheimer’s, dementia with Lewy bodies, frontotemporal dementia, as well as
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
He has spent a majority of his career at Pfizer, where he held a number of senior roles including medical director for Pfizer Switzerland, European team leader for the Alzheimer's ... disease drug Aricept and medical team leader for its anti-inflammatory
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
No results were found
The nzyme group focuses on the three fundamentals that enable full patient access - Education, Access & Activation. Our specialist...